MendeliKABS Information

MendeliKABS is a pharmaceutical company dedicated to the treatment of rare diseases. The organization integrates expertise in treatment of orphan diseases and drugs manufacturing, in compliance with international regulations and standards. Inspired by the principle of offering premium quality affordable solutions to persons afflicted with hereditary tyrosinemia type 1, MendeliKABS' vision embraces expanded access to orphan drugs in order to effectively meet the needs of patients affected by rare diseases. Produced in three dosages, 2 mg, 5 mg and 10 mg, MDK-Nitisinone is manufactured in Quebec, Canada. Since its introduction in 1991, this treatment has replaced liver transplantation as a first line treatment for patients with this rare condition. Classified as an orphan disease, hereditary tyrosinemia type 1 affects one person out of 200,000 worldwide, but is especially prevalent in the province of Québec, Canada, with about one hundred persons affected.